Emyria Acquires Pax Centre to Lead Psychedelic Therapy

Emyria Limited (ASX: EMD), a mental health-focused clinical services and drug development company, has successfully acquired Mind Body Consulting Pty Ltd, operating as the Pax Centre. The strategic acquisition, valued at AU$1.7 million, signifies Emyria's commitment to reshaping mental health care and drug development in Australia and beyond.

As a result of this acquisition, Emyria is poised to offer psychedelic-assisted therapy to qualified patients, having secured MDMA supply, trained therapists, obtained ethics approval for MDMA-assisted therapy for PTSD, and established a patient data registry. Emyria is also expanding its offerings to include ketamine and psilocybin-assisted therapies, with Authorised Prescriber applications in progress.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com